Novo Nordisk: Trial data of oral weight-loss drug comparable to Wegovy, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

The Phase IIIa study within the so-called OASIS programme involved 667 adults with obesity or who were overweight with one or more comorbidities. The treatment was in conjunction with lifestyle intervention. The company informed that participants who adhered to the treatment on average experienced a weight loss of 17.4 per cent after 68 weeks compared with only 1.8 per cent of the those that took the placebo., The Phase IIIa study within the so-called OASIS programme involved 667 adults with obesity or who were overweight with one or more comorbidities. The treatment was in conjunction with lifestyle intervention. The company informed that participants who adhered to the treatment on average experienced a weight loss of 17.4 per cent after 68 weeks compared with only 1.8 per cent of the those that took the placebo., , Read More